US Stock MarketDetailed Quotes

CPRX Catalyst Pharmaceuticals

Watchlist

21.350
-0.720-3.26%

Close Dec 18 16:00 ET

21.400
+0.050+0.23%

Pre 08:58 ET

2.55BMarket Cap18.09P/E (TTM)

Catalyst Pharmaceuticals Stock Forum

轉生成最廢資本家

Nov 13 14:21

Great Companies But No One Knows

$Catalyst Pharmaceuticals (CPRX.US)$

Tonyco

Oct 13 19:16

$KinderCare Learning Companies (KLC.US)$
$Catalyst Pharmaceuticals (CPRX.US)$
eyooooooo

Stock_Drift

Sep 24 05:04

$Catalyst Pharmaceuticals (CPRX.US)$

Iwill TradeScared

Aug 29 08:04

$Catalyst Pharmaceuticals (CPRX.US)$ P/L= +0.5% in 8 days

Iwill TradeScared

Aug 21 13:31

$Catalyst Pharmaceuticals (CPRX.US)$

Trytosaveabit

Jul 24 07:12

Update

$Catalyst Pharmaceuticals (CPRX.US)$ Catalyst Pharmaceuticals Enters Exclusive License, Supply And Commercialization Agreement Granting Kye Pharmaceuticals Canadian Rights To AGAMREE For Duchenne Muscular Dystrophy

Meltyy

May 24 03:20

See remaining FDA PDUFAs in May 👀👇
$Bristol-Myers Squibb (BMY.US)$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna (MRNA.US)$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals (CPRX.US)$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline (GSK.US)$ : Arexvy
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : Elafibranor
$Regeneron Pharmaceuticals (REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb (BMY.US)$ : Augtyro...

Trytosaveabit

May 8 15:21

Solid

$Catalyst Pharmaceuticals (CPRX.US)$ May 08 (Reuters) - Catalyst Pharmaceuticals Q1 Net Income USD 23.3 Million.
Q1 Adjusted Net Income USD 46.8 Million Vs. Ibes Estimate USD 23.7 Million
Q1 Operating Income USD 27.1 Million Vs. Ibes Estimate USD 25.1 Million
Outlook FY Revenue USD 455-475 Million

Moomoo AI

Mar 22 09:45

The absence of insider buying at Catalyst Pharmaceuticals over the past year is concerning. However, the high level of insider ownership indicates alignment with shareholder interests. Insider selling, even below the current price, raises questions about their view on the company's valuation.